Johnson & Johnson reports two-year data for IMAAVY in gMG

Johnson & Johnson announced long-term data on IMAAVY (nipocalimab-aahu) across 15 abstracts prepared for the 2026 Myasthenia Gravis Foundation of America Scientific Session and the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on September 29, 2026. The therapy is approved by the FDA and EMA for pediatric patients aged 12 and older with anti-AChR or anti-MuSK antibody-positive generalized myasthenia gravis (gMG).

Two-year results from the Vibrance-MG Phase 2/3 long-term extension study in anti-AChR+ adolescents showed sustained symptom control through Week 108. Participants experienced mean changes from baseline of -2.88 points in the MG-ADL score and -8.25 points in the QMG score. Among six adolescent patients receiving corticosteroids at entry, three reduced their dose and one stopped treatment entirely, with no new safety signals reported.

A retrospective survey of healthcare professionals reviewing 97 adult gMG patients who switched to IMAAVY showed that fluctuating symptom control was the leading reason for halting prior advanced therapies, cited in 54.6% of cases. The primary reasons for starting IMAAVY were a consistent treatment schedule (62.9%) and hope for improved efficacy (56.7%). Clinicians reported that 73.2% of transitioned patients were much improved or very much improved, while 76.4% on prednisone reduced their dose and 5.5% discontinued it.